|
California Institute of Molecular Medicine (CIMM) was established in 1997 to provide "space" for a group of scientists to develop methodology for culturing human hepatitis-C virus (HCV) in-vitro. The goal was to eventually develop a rational therapy to treat HCV infection, and answer important questions that remain unanswered even today. Since it’s founding, CIMM has made significant progress towards their goals. We are proud to have Dr. Ann Kelley, Hematologist/Oncologist, as the president of CIMM.
 |
 |
|
Graphic Presentation
of Human Liver
|
Human Hepatitis C Virus particles
grown in-vitro at CIMM
|
|
| Current CIMM Programs |
| • |
|
Study of HCV for scientific reports |
|
|
|
| • |
|
Further definition of HCV for patent purposes |
|
|
|
| • |
|
Studies of human neuronal cells in cell culture |
|
|
|
| • |
|
Development of Kupffer cell culture in vitro, and its therapeutic applications |
|
|
|
| • |
|
Reporting our findings of pro-endothelial cells from bone marrow |
|
|
|
| • |
|
Address the long term studies of human RNA and DNA viruses, and their roles in a variety of diseases |
|
|
|
| • |
|
Conclude the studies of various strains of Feline Leukemia Virus (FeLV) and develop a rational therapy |
|
|
|
| • |
|
Possible association of FeLV with other human diseases |
|
|
|
| • |
|
Therapy approaches for HHV-6 infection |
|
|
|
| • |
|
Improve the production of HTLV-1 and HTLV-2 in cell culture |
|